Pathophysiology and Treatment of Atopic Dermatitis and Psoriasis, 2nd Edition

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 March 2025 | Viewed by 1780

Special Issue Editor

Department of Dermatology, Kangnam Sacred Heart Hospital, Hallym University, Seoul, Republic of Korea
Interests: atopic dermatitis; psoriasis; transcriptome
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In the past few decades, research on atopic dermatitis and psoriasis has been very active. As a result, researchers have found that many biological and small-molecule drugs that target these two diseases are under development or are actually being prescribed to patients in clinical settings. However, more molecular, immunological, and neurological mechanisms and clinical studies are needed for precise medical treatment according to the patient's endotype and phenotype for each biomarker.

Atopic dermatitis and psoriasis are typical chronic inflammatory skin diseases. These were thought to be very different diseases caused by Th2 and Th1 immunological bias, respectively. However, many studies have revealed that the Th17/Th22 pathway in these two diseases has a common influence on disease initiation and chronicity. In addition to immunological abnormalities, atopic dermatitis and psoriasis have shared pathophysiology, such as abnormal skin barrier function, pruritus, genetic mutations, environmental influences, and neurophysiological abnormalities. Therefore, interesting results are often obtained when comparing these two diseases.

In this section, we welcome all research papers on molecular biology, immunology, neurophysiology, and biomarkers of atopic dermatitis and psoriasis, or research papers comparing the pathophysiology and treatment modalities of the two diseases.

Dr. Hyeone Kim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atopic dermatitis
  • biomarker endotypes
  • mutation
  • next-generation sequencing
  • phenotypes
  • psoriasis
  • transcriptome

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 1225 KiB  
Article
Exposure to Volatile Organic Compounds May Contribute to Atopic Dermatitis in Adults
by Kuo-Tung Tang, Yu-Sin Chen, Mey-Fann Lee, Tzu-Ting Chen, Chien-Chen Lai, Chi-Chien Lin and Yi-Hsing Chen
Biomedicines 2024, 12(7), 1419; https://doi.org/10.3390/biomedicines12071419 - 26 Jun 2024
Viewed by 1451
Abstract
Background: Volatile organic compounds (VOC) are major indoor air pollutants. Previous studies reported an association between VOC exposure and allergic diseases. Here, we aimed to explore the relationship between VOC exposure and atopic dermatitis (AD) in adults. Methods: We prospectively enrolled 31 adult [...] Read more.
Background: Volatile organic compounds (VOC) are major indoor air pollutants. Previous studies reported an association between VOC exposure and allergic diseases. Here, we aimed to explore the relationship between VOC exposure and atopic dermatitis (AD) in adults. Methods: We prospectively enrolled 31 adult AD patients and 11 healthy subjects as controls. Urine metabolite levels of VOCs, including 1.3-butadiene, acrylamide, benzene, toluene, and xylene, were all determined with liquid chromatography–mass spectrometry. The relationship between AD and log-transformed urine levels of VOC metabolites were examined using a multivariate linear regression model adjusted for age and sex. We also treated mouse bone marrow-derived cells (BMMCs) with 1,3-butadiene and toluene and measured the release of β-hexosaminidase. Results: Our results demonstrated that creatinine-corrected urine levels of N-Acetyl-S- (3,4-dihydroxybutyl)-L-cysteine (DHBMA), N-Acetyl-S-(2-carbamoyl-2-hydroxyethyl)-L-cysteine (GAMA), and N-Acetyl-S-(benzyl)-L-cysteine (BMA) were all elevated in AD patients compared with controls. In a multivariate linear regression model, creatinine-corrected urine levels of BMA (a toluene metabolite) and DHBMA (a 1,3-butadiene metabolite) appeared elevated in AD patients, although statistical significance was not reached after correction for multiple comparisons. In addition, 1,3-butadiene and toluene could stimulate BMMCs to degranulate as much as compound 48/80. Conclusions: Some VOCs, such as 1,3-butadiene and toluene, might be associated with AD pathogenesis in adults. Full article
Show Figures

Figure 1

Back to TopTop